Ventricular arrhythmias in heart failure.

The management of ventricular arrhythmias in patients with heart failure continues to pose many challenges. Three principles of therapy can be identified: (1) Empiric therapy is not warranted for asymptomatic ventricular arrhythmias. (2) Therapy for asymptomatic ventricular arrhythmias must be individualized. Appropriate management of the underlying cardiac disease is critical, and careful identification of therapeutic goals is necessary. (3) Patients at high risk should be included in prospective, controlled clinical trials whenever possible.

[1]  S. Connolly,et al.  Post‐Myocardial Infarction Mortality in Patients With Ventricular Premature Depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study , 1991, Circulation.

[2]  D L Ross,et al.  Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. , 1986, Circulation.

[3]  I. Palacios,et al.  Exercise capacity and systolic and diastolic ventricular function after recovery from acute dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.

[4]  K. Lee,et al.  Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). , 1993, Progress in cardiovascular diseases.

[5]  J. Ruskin,et al.  Risk identification for sudden cardiac death--implications for implantable cardioverter-defibrillator use. , 1993, Progress in cardiovascular diseases.

[6]  D. Wilber,et al.  Nonsustained ventricular tachycardia and other high-risk predictors following myocardial infarction: implications for prophylactic automatic implantable cardioverter-defibrillator use. , 1993, Progress in cardiovascular diseases.

[7]  B. Olshansky,et al.  The Clinical Significance of Nonsustained Ventricular Tachycardia: Current Perspectives , 1994, Pacing and clinical electrophysiology : PACE.

[8]  G. Fonarow,et al.  Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. , 1994, Journal of the American College of Cardiology.

[9]  H. Wellens,et al.  Ventricular arrhythmias in heart failure. , 1992, The American journal of cardiology.

[10]  J. Goin,et al.  Quinidine‐Related Mortality in the Short‐to‐Medium‐Term Treatment of Ventricular Arrhythmias: A Meta‐Analysis , 1991, Circulation.

[11]  A. Moss.  Influence of the implantable cardioverter defibrillator on survival: retrospective studies and prospective trials. , 1993, Progress in cardiovascular diseases.

[12]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[13]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[14]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[15]  M. Pfisterer,et al.  Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) , 1990, Journal of the American College of Cardiology.

[16]  E. Prystowsky,et al.  Role of electrophysiologic testing in managing patients who have ventricular tachycardia unrelated to coronary artery disease. , 1982, The American journal of cardiology.